Flputnam Investment Management Co. Sells 87,651 Shares of Pfizer Inc. $PFE

Key Points

• Flputnam Investment Management Co. decreased its holdings in Pfizer Inc. by 44.9%, selling 87,651 shares and ending the quarter with 107,606 shares valued at $2,727,000.
• Brokerages have adjusted price targets for Pfizer, with Morgan Stanley raising theirs from $32.00 to $33.00, while Berenberg Bank lowered theirs from $28.00 to $25.00, reflecting a range of buy to hold ratings.
• Pfizer recently reported earnings of $0.78 per share, exceeding estimates of $0.58, with a 10.3% revenue increase year-over-year, while announcing a quarterly dividend of $0.43, yielding 7.0%.

Flputnam Investment Management Co. lowered its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 44.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 107,606 shares of the biopharmaceutical company's stock after selling 87,651 shares during the quarter. Flputnam Investment Management Co.'s holdings in Pfizer were worth $2,727,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Brighton Jones LLC raised its holdings in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC raised its holdings in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after purchasing an additional 2,087 shares during the last quarter. Triumph Capital Management increased its stake in shares of Pfizer by 20.0% in the 4th quarter. Triumph Capital Management now owns 10,283 shares of the biopharmaceutical company's stock valued at $273,000 after acquiring an additional 1,717 shares during the last quarter. BIP Wealth LLC increased its stake in shares of Pfizer by 11.1% in the 4th quarter. BIP Wealth LLC now owns 11,853 shares of the biopharmaceutical company's stock valued at $314,000 after acquiring an additional 1,180 shares during the last quarter. Finally, Chapman Financial Group LLC bought a new stake in shares of Pfizer in the 4th quarter valued at about $563,000. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Pfizer stock traded down $0.23 during mid-day trading on Wednesday, hitting $24.76. 30,706,896 shares of the company's stock traded hands, compared to its average volume of 45,018,609. The firm has a 50 day simple moving average of $24.82 and a two-hundred day simple moving average of $24.37. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The stock has a market cap of $140.75 billion, a price-to-earnings ratio of 13.17, a P/E/G ratio of 0.88 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter last year, the business earned $0.60 earnings per share. Pfizer's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer's payout ratio is currently 91.49%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on PFE shares. HSBC cut their price target on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. Morgan Stanley lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Jefferies Financial Group raised their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, May 21st. Berenberg Bank decreased their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Thursday, May 29th. Finally, Citigroup raised their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Pfizer currently has a consensus rating of "Hold" and a consensus target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.